Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE): 3 pipeline candidates · ~51 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
50.9 months
23% dilution
Lead: Phase 1
3 candidates
N/A
6 buys · 0 sells (180d)
A transparent, data-derived signal for Aprea Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.7M
Cash
$46.5M
Quarterly Burn
$2.8M
Runway
50.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$482K
| Holder | Shares | Value |
|---|---|---|
| sphera funds management ltd. | 270,000 | $206K |
| geode capital management, llc | 119,131 | $91K |
| bnp paribas financial markets | 39,817 | $30K |
| vanguard capital management llc | 39,244 | $30K |
| vanguard fiduciary trust co | 38,464 | $29K |
| renaissance technologies llc | 25,100 | $19K |
| morgan stanley | 22,330 | $17K |
| lpl financial llc | 21,052 | $16K |
| hightower advisors, llc | 13,864 | $11K |
| two sigma securities, llc | 13,500 | $10K |
Showing top 10 of 18 institutional holders of Aprea Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aprea Therapeutics, Inc.'s pipeline?
Aprea Therapeutics, Inc. (APRE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aprea Therapeutics, Inc.'s lead drug candidate?
Aprea Therapeutics, Inc.'s most advanced tracked candidate is APR-1051 (Phase 1) for Advanced solid tumors (including PPP2R1A-mutated uterine serous carcinoma, FBXW7-mutated colon cancer, HPV+ oropharyngeal squamous cell carcinoma, cervical, vaginal, or vulvar squamous cell carcinoma).
What is Aprea Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aprea Therapeutics, Inc. has approximately 50.9 months of cash runway.
What is Aprea Therapeutics, Inc.'s market capitalization?
Aprea Therapeutics, Inc.'s market capitalization is approximately $8.7M.
Who is the CEO of Aprea Therapeutics, Inc.?
Dr. Oren Gilad Ph.D. is the chief executive officer of Aprea Therapeutics, Inc. (APRE).
Get the full picture on Aprea Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.